title: The serotonergic system in Parkinson's disease.
abstract: Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding.
authors: Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.
authors: Philippe
authors: P
authors: Huot
authors: Susan H
authors: SH
authors: Fox
authors: Jonathan M
authors: JM
authors: Brotchie
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D058990:Molecular Targeted Therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D020033:Protein Isoforms / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D011985:Receptors, Serotonin / Q000737:chemistry / Q000378:metabolism*; D059326:Serotonergic Neurons / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000737:chemistry / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D020033:Protein Isoforms; D011985:Receptors, Serotonin; D012701:Serotonin